THERAPY DOSSIER · th-0451342b0236

Prothymosin alpha (ProTalpha) and its mimetic hexapeptide P6Q, co-administered with tissue plasminogen activator

Biologic · Prothymosin alpha and mimetic hexapeptide P6Q, with tPA; protein/peptide biologic.

Evidence & regulatory context

Mechanism: Prothymosin alpha and mimetic hexapeptide P6Q, with tPA; protein/peptide biologic.
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31454420 ↗2019Reported benefit

Prothymosin alpha and its mimetic hexapeptide improve delayed tissue plasminogen activator-induced brain damage following cerebral ischemia.

MouseIschaemia-reperfusionCerebral (MCAO/stroke)C57BL/6MaleProTalpha co-administered with tissue plasminogen activator at 4.5 h, or given…

Model: Middle cerebral artery occlusion and photochemically induced thrombosis, with delayed tissue plasminogen activator administration

Co-administration of ProTalpha or P6Q abolished haemorrhage induced by tissue plasminogen activator given at 4.5 h, reversed vascular damage and matrix metalloproteinase upregulation at 6 h, and improved motor function and survival beyond 7 days with the two-dose schedules.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…